JP2021506891A - 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ[4,5−c]キノリン化合物 - Google Patents
免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ[4,5−c]キノリン化合物 Download PDFInfo
- Publication number
- JP2021506891A JP2021506891A JP2020534235A JP2020534235A JP2021506891A JP 2021506891 A JP2021506891 A JP 2021506891A JP 2020534235 A JP2020534235 A JP 2020534235A JP 2020534235 A JP2020534235 A JP 2020534235A JP 2021506891 A JP2021506891 A JP 2021506891A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- group
- och
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000028993 immune response Effects 0.000 title abstract description 9
- 125000005647 linker group Chemical group 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title description 35
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title description 4
- 150000002460 imidazoles Chemical class 0.000 title 1
- 108091008020 response regulators Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 298
- 241001465754 Metazoa Species 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims description 230
- 229910052739 hydrogen Inorganic materials 0.000 claims description 165
- 239000001257 hydrogen Substances 0.000 claims description 165
- 125000000217 alkyl group Chemical group 0.000 claims description 128
- 150000002431 hydrogen Chemical group 0.000 claims description 88
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 67
- 125000002947 alkylene group Chemical group 0.000 claims description 56
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 36
- 230000001939 inductive effect Effects 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 239000012646 vaccine adjuvant Substances 0.000 claims description 15
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 102000006992 Interferon-alpha Human genes 0.000 claims description 12
- 108010047761 Interferon-alpha Proteins 0.000 claims description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 10
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 150000002367 halogens Chemical group 0.000 claims description 2
- -1 imidazo [4,5-c] quinoline compound Chemical class 0.000 abstract description 69
- 102000004127 Cytokines Human genes 0.000 abstract description 39
- 108090000695 Cytokines Proteins 0.000 abstract description 39
- 201000010099 disease Diseases 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 23
- 238000011282 treatment Methods 0.000 abstract description 22
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000001613 neoplastic effect Effects 0.000 abstract description 9
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 230000002458 infectious effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 241000282412 Homo Species 0.000 description 64
- 239000000203 mixture Substances 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 38
- QRZMXADUXZADTF-UHFFFAOYSA-N 4-aminoimidazole Chemical compound NC1=CNC=N1 QRZMXADUXZADTF-UHFFFAOYSA-N 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 23
- 229960005486 vaccine Drugs 0.000 description 23
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 17
- 239000006188 syrup Substances 0.000 description 16
- 235000020357 syrup Nutrition 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 229910004298 SiO 2 Inorganic materials 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000003840 hydrochlorides Chemical class 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 8
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 208000030852 Parasitic disease Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ZRFUZDDJSQVQBY-UHFFFAOYSA-N 4-chloro-3-nitroquinoline Chemical compound C1=CC=CC2=C(Cl)C([N+](=O)[O-])=CN=C21 ZRFUZDDJSQVQBY-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- QEALYLRSRQDCRA-UHFFFAOYSA-N myristamide Chemical compound CCCCCCCCCCCCCC(N)=O QEALYLRSRQDCRA-UHFFFAOYSA-N 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 3
- 229940008406 diethyl sulfate Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical class CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- SKPRPEJLFKCOAB-UHFFFAOYSA-N 3-nitroquinolin-4-amine Chemical compound C1=CC=C2C(N)=C([N+]([O-])=O)C=NC2=C1 SKPRPEJLFKCOAB-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N alpha-octadecene Natural products CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229960005004 cholera vaccine Drugs 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 2
- 150000008050 dialkyl sulfates Chemical class 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- HSEMFIZWXHQJAE-UHFFFAOYSA-N hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 2
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 2
- BTJRKNUKPQBLAL-UHFFFAOYSA-N hydron;4-methylmorpholine;chloride Chemical compound Cl.CN1CCOCC1 BTJRKNUKPQBLAL-UHFFFAOYSA-N 0.000 description 2
- OOCSVLHOTKHEFZ-UHFFFAOYSA-N icosanamide Chemical compound CCCCCCCCCCCCCCCCCCCC(N)=O OOCSVLHOTKHEFZ-UHFFFAOYSA-N 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 2
- 229940038384 octadecane Drugs 0.000 description 2
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- FODWRUPJCKASBN-UHFFFAOYSA-M tetrabutylazanium;chloride;hydrate Chemical compound O.[Cl-].CCCC[N+](CCCC)(CCCC)CCCC FODWRUPJCKASBN-UHFFFAOYSA-M 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229960001515 yellow fever vaccine Drugs 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- NMDDZEVVQDPECF-LURJTMIESA-N (2s)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@H](N)C(O)=O NMDDZEVVQDPECF-LURJTMIESA-N 0.000 description 1
- KMPBBRFCAYFTMR-ZETCQYMHSA-N (2s)-2,8-diaminooctanoic acid Chemical compound NCCCCCC[C@H](N)C(O)=O KMPBBRFCAYFTMR-ZETCQYMHSA-N 0.000 description 1
- RWQCKACYKKSOKK-AWEZNQCLSA-N (2s)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC(C)(C)OC(=O)NCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 RWQCKACYKKSOKK-AWEZNQCLSA-N 0.000 description 1
- QKEWQOJCHPFEAF-YFKPBYRVSA-N (3S)-3,6-diaminohexanoic acid Chemical compound NCCC[C@H](N)CC(O)=O QKEWQOJCHPFEAF-YFKPBYRVSA-N 0.000 description 1
- XQKAYTBBWLDCBB-VKHMYHEASA-N (3s)-3,4-diaminobutanoic acid Chemical compound NC[C@@H](N)CC(O)=O XQKAYTBBWLDCBB-VKHMYHEASA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- XUXVVQKJULMMKX-UHFFFAOYSA-N 1,1,1-trimethoxypentane Chemical group CCCCC(OC)(OC)OC XUXVVQKJULMMKX-UHFFFAOYSA-N 0.000 description 1
- HYHOMJCJTKMXLW-LTCKWSDVSA-N 1-[(2S)-5-amino-1-ethoxypentan-2-yl]imidazo[4,5-c]quinolin-4-amine dihydrochloride Chemical compound Cl.Cl.NCCC[C@@H](COCC)N1C=NC=2C(=NC=3C=CC=CC=3C=21)N HYHOMJCJTKMXLW-LTCKWSDVSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- ZQRCDAUYTDAAIK-UHFFFAOYSA-N 1-oxo-[1,3]thiazolo[4,5-c]quinolin-4-amine Chemical compound S1(C=NC=2C(=NC=3C=CC=CC=3C=21)N)=O ZQRCDAUYTDAAIK-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-REOHCLBHSA-N 3-amino-L-alanine Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HPWFSRBTNXKYHX-UHFFFAOYSA-N 4-amino-2,3-dihydropyrazolo[3,4-c]quinolin-1-one Chemical compound C1(NNC=2C(=NC=3C=CC=CC=3C=21)N)=O HPWFSRBTNXKYHX-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PKMJQSKDDHWUIB-NRFANRHFSA-N CCCCCCCCCC(NCCC[C@@H](COCC)[n]1c2c(cccc3)c3nc(N)c2nc1)=O Chemical compound CCCCCCCCCC(NCCC[C@@H](COCC)[n]1c2c(cccc3)c3nc(N)c2nc1)=O PKMJQSKDDHWUIB-NRFANRHFSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940037642 autologous vaccine Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical class ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229940124737 hepatitis-C vaccine Drugs 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940033324 influenza A vaccine Drugs 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 229940014135 meningitis vaccine Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical class CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical group 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000017058 pharyngeal squamous cell carcinoma Diseases 0.000 description 1
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VMSNAGJCAFKZOF-JTQLQIEISA-N tert-butyl N-[(4S)-4-amino-5-ethoxypentyl]carbamate Chemical compound N[C@@H](CCCNC(OC(C)(C)C)=O)COCC VMSNAGJCAFKZOF-JTQLQIEISA-N 0.000 description 1
- YFDWGXVZFIAABK-QMMMGPOBSA-N tert-butyl n-[(4s)-4-amino-5-hydroxypentyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC[C@H](N)CO YFDWGXVZFIAABK-QMMMGPOBSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960001266 typhoid vaccines Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229940021648 varicella vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本出願は、2017年12月20日に出願された米国特許仮出願第62/608334号の優先権を主張するものであり、その開示の全体が参照により本明細書に組み込まれる。
いくつかの薬剤化合物は、免疫システムの特定の重要な側面を刺激することによって、及び特定の他の側面を抑制することによって、作用する(例えば、米国特許第6,039,969号(Tomai et al.)、及び同第6,200,592号(Tomai et al.))。これらの化合物は、時として、免疫応答調節剤(immune response modifier、IRM)と呼ばれる。いくつかのIRM化合物は、ウイルス性疾患、腫瘍形成、及びTH2−媒介性疾患を処置するのに有用である。いくつかのIRM化合物は、ワクチンアジュバントとして有用である。
Rは、ハロゲン、ヒドロキシ、アルキル、アルコキシ、及び−C(O)−O−アルキルからなる群から選択され、
nは、0又は1の整数であり、
Xはアルキレンであり、このアルキレン基は、1つ以上の−O−基により任意に介在されていてもよく、
R1は、C1−5アルキル及び−C1−3アルキレン−O−C1−3アルキルからなる群から選択され、
R2は、水素、メチル、エチル、n−プロピル、n−ブチル、−CH2OCH3、−CH2OCH2CH3、及び−CH2CH2OCH3からなる群から選択され、
R3はアルキルであり、このアルキル基は、1つ以上の−O−基により任意に介在されていてもよく、
R4は、水素、メチル、エチル、n−プロピル、及びイソプロピルからなる群から選択される。
本開示の医薬組成物も想到される。本開示の医薬組成物は、本開示(本明細書に記載)の化合物又は塩の治療有効量を、製薬上許容される担体と組み合わせて含有する。
ウイルス性疾患、例えば、アデノウイルス、ヘルペスウイルス(例えば、HSV−I、HSV−II、CMV、若しくはVZV)、ポックスウイルス(例えば、天然痘若しくはワクシニアなどのオルソポックスウイルス、又は伝染性軟属腫)、ピコルナウイルス(例えば、ライノウイルス若しくはエンテロウイルス)、オルソミクソウイルス(例えば、インフルエンザウイルス、鳥インフルエンザ)、パラミクソウイルス(例えば、パラインフルエンザウイルス、ムンプスウイルス、麻疹ウイルス、及び呼吸器合胞体ウイルス(respiratory syncytial virus、RSV)、コロナウイルス(例えば、SARS)、パポバウイルス(例えば、性器疣贅、尋常性疣贅、又は足底疣贅を引き起こすものなどのパピローマウイルス)、ヘパドナウイルス(例えば、B型肝炎ウイルス)、フラビウイルス(例えば、C型肝炎ウイルス若しくはデングウイルス)、又はレトロウイルス(例えば、HIVなどのレンチウイルス)、エボラウイルスによる感染によって引き起こされる疾患。
アトピー性皮膚炎又は湿疹、好酸球増加、喘息、アレルギー、アレルギー性鼻炎、及びオメン症候群などのTH2媒介性アトピー性疾患;
創傷修復に関連する疾患、例えば、ケロイド形成及び他のタイプの瘢痕化の阻害(例えば、慢性創傷を含めた創傷治療の促進)など;
マラリア、リーシュマニア症、クリプトスポリジア症、トキソプラズマ症、及びトリパノソーマ感染症を含むがこれらに限定されない寄生生物性疾患が挙げられる。
実施形態1は、式(I)
nは、0又は1の整数であり、
Rは、ハロゲン、ヒドロキシ、アルキル、アルコキシ、及び−C(O)−O−アルキルからなる群から選択され、
Xはアルキレンであり、このアルキレン基は、1つ以上の−O−基により任意に介在されていてもよく、
R1は、C1−5アルキル及び−C1−3アルキレン−O−C1−3アルキルからなる群から選択され、
R2は、水素、メチル、エチル、n−プロピル、n−ブチル、−CH2OCH3、−CH2OCH2CH3、及び−CH2CH2OCH3からなる群から選択され、
R3はアルキルであり、このアルキル基は、1つ以上の−O−基により任意に介在されていてもよく、
R4は、水素、メチル、エチル、n−プロピル、及びイソプロピルからなる群から選択される]の化合物、又は製薬上許容されるその塩である。
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]アセトアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]プロパンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]−2−メチルプロパンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ブタンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]−3−メチルブタンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ペンタンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ヘキサンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]オクタンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ノナンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]デカンアミドからなる群から選択される化合物、又は製薬上許容されるその塩である。
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ドデカンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]テトラデカンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ヘキサデカンアミドからなる群から選択される化合物、又は製薬上許容されるその塩である。
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]オクタデカンアミド、
N−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]エイコサンアミド
からなる群から選択される化合物、又は製薬上許容されるその塩である。
nは、0又は1の整数であり、
Rは、ハロゲン、ヒドロキシ、アルキル、アルコキシ、及び−C(O)−O−アルキルからなる群から選択され、
Xはアルキレンであり、このアルキレン基は、1つ以上の−O−基により任意に介在されていてもよく、
R1は、C1−5アルキル及び−C1−3アルキレン−O−C1−3アルキルからなる群から選択され、
R2は、水素、メチル、エチル、n−プロピル、及びn−ブチル、−CH2OCH3、−CH2OCH2CH3、及び−CH2CH2OCH3からなる群から選択され、
R3はアルキルであり、このアルキル基は、1つ以上の−O−基により任意に介在されていてもよく、
R4は、水素、メチル、エチル、n−プロピル、及びイソプロピルからなる群から選択される]の化合物、又は製薬上許容されるその塩である。
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]アセトアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]プロパンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]−2−メチルプロパンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ブタンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]−3−メチルブタンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ペンタンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ヘキサンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]オクタンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ノナンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]デカンアミドからなる群から選択される化合物、又は製薬上許容されるその塩である。
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ドデカンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]テトラデカンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]ヘキサデカンアミドからなる群から選択される化合物、又は製薬上許容されるその塩である。
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]オクタデカンアミド、
N−[4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]エイコサンアミド
からなる群から選択される化合物、又は製薬上許容されるその塩である。
15mLの無水テトラヒドロフラン(tetrahydrofuran、THF)に溶解させたN−δ−BOC−N−α−CBZ−L−オルニチン(4.71g、12.9mmol)の撹拌溶液を、氷/メタノール浴において−15℃に冷却した。この溶液をN−メチルモルホリン(1.42mL、12.9mmol)と組み合わせ、続いてエチルクロロホルメート(1.23mL、12.9mmol)を添加した。5分間撹拌した後、反応混合物を濾過し、少量のTHFですすぎ、N−メチルモルホリン塩酸塩を除去した。得られた濾液を冷浴に戻し、7mLの水中、1.00gのNaBH4の溶液を注意深く添加した。20分間撹拌した後、反応混合物を100mLの水と組み合わせ、続いて75mLの酢酸エチルを添加した。この層を分離し、有機部分を水及び飽和食塩水で洗浄し、Na2SO4で乾燥させ、濾過し、濃縮して無色のシロップを得た。シロップをヘプタンから濃縮して、白色固体として、3.62gのtert−ブチルN−[(4S)−4−(ベンジルオキシカルボニルアミノ)−5−ヒドロキシ−ペンチル]カルバメートをもたらした。
20mLのトルエンに溶解させたN−[(4S)−4−(ベンジルオキシカルボニルアミノ)−5−ヒドロキシ−ペンチル]カルバメート(3.62g、10.3mmol)の撹拌溶液を、1.15gの50%NaOH溶液及びジエチルサルフェート(1.61mL、12.3mmol)と組み合わせた。次いで、テトラブチルアンモニウムクロリド水和物(200mg)を、反応混合物に添加した。2時間撹拌した後、反応混合物を10mLの飽和NH4OH溶液でクエンチし、更に75分間撹拌した。次いで、反応物を水と組み合わせ、層同士を分離した。有機層を水(2×)及び飽和食塩水で連続的に洗浄し、Na2SO4で乾燥させ、濾過し、減圧下で濃縮して、無色のシロップを得た。カラムクロマトグラフィー(SiO2、20%酢酸エチル/ヘキサンから50%酢酸エチル)による精製は、白色結晶固体として、0.37gのtert−ブチルN−[(4S)−4−(ベンジルオキシカルボニルアミノ)−5−エトキシ−ペンチル]カルバメートをもたらした。
メタノール中のtert−ブチルN−[(4S)−4−(ベンジルオキシカルボニルアミノ)−5−エトキシ−ペンチル]カルバメート(0.37g、0.97mmol)の溶液を圧力ボトルに入れ、40mgの炭素担持10%パラジウムを添加した。次いで、水素(40PSI)雰囲気下、ボトルを終夜振盪した。反応混合物をセライトのパッドを通して濾過し、メタノールですすぎ、減圧下で濾液を濃縮して、無色のシロップとして、197mgのtert−ブチルN−[(4S)−4−アミノ−5−エトキシ−ペンチル]カルバメートを得た。
15mLのジクロロメタンに溶解させたtert−ブチルN−[(4S)−4−アミノ−5−エトキシ−ペンチル]カルバメート(197mg、0.801mmol)の溶液を、4−クロロ−3−ニトロキノリン(166mg、0.801mmol)及びトリエチルアミン(223μL、1.60mmol)と組み合わせ、反応混合物を窒素雰囲気下で終夜撹拌した。反応混合物を濃縮し、黄色固体を得た。この固体を、20mLの酢酸エチルに溶解させ、水(3×)及び飽和食塩水で洗浄した。有機部分をNa2SO4で乾燥させ、濾過し、濃縮して、黄色固体を得た。カラムクロマトグラフィー(SiO2、20%酢酸エチル/ヘキサンから50%酢酸エチル)による精製は、黄色固体として、283mgのtert−ブチルN−[(4S)−5−エトキシ−4−[(3−ニトロ−4−キノリル)アミノ]ペンチル]カルバメートをもたらした。
15mLのアセトニトリル中のtert−ブチルN−[(4S)−5−エトキシ−4−[(3−ニトロ−4−キノリル)アミノ]ペンチル]カルバメート(283mg、0.677mmol)の懸濁液を圧力ボトルに入れ、次いで、80mgの炭素担持3%白金を添加した。次いで、水素(40PSI)雰囲気下、ボトルを90分間振盪した。反応混合物をセライトのパッドを通して濾過し、アセトニトリルですすぎ、減圧下で濾液を濃縮して、橙色の泡として、262mgのtert−ブチルN−[(4S)−4−[(3−アミノ−4−キノリル)アミノ]−5−エトキシ−ペンチル]カルバメートを得た。
10mLの酢酸n−プロピル中に溶解させたtert−ブチルN−[(4S)−4−[(3−アミノ−4−キノリル)アミノ]−5−エトキシ−ペンチル]カルバメート(262mg、0.67mmol)の溶液を、トリエチルオルトホルメート(0.32mL、1.92mmol)及び50mgのピリジン塩酸塩と組み合わせ、混合物を105℃に終夜加熱した。冷却した反応混合物を25mLの酢酸エチルで希釈し、飽和NaHCO3溶液、水、及び飽和食塩水で連続的に洗浄した。有機部分をNa2SO4で乾燥させ、濾過し、濃縮して、淡褐色のシロップを得た。カラムクロマトグラフィー(SiO2、2.5%メタノール/クロロホルムから5%メタノール/クロロホルム)による精製は、淡琥珀色のシロップとして、200mgのtert−ブチルN−[(4S)−5−エトキシ−4−イミダゾ[4,5−c]キノリン−1−イル−ペンチル]カルバメートをもたらした。
5mLのジクロロメタンに溶解させたtert−ブチルN−[(4S)−5−エトキシ−4−イミダゾ[4,5−c]キノリン−1−イル−ペンチル]カルバメート(200mg、0.497mmol)の溶液を、3−クロロ過安息香酸(150mg、57〜86%)と組み合わせ、反応物を45分間撹拌した。反応混合物を、1mLの濃NH4OH溶液及びp−トルエンスルホニルクロリド(104mg、0.547mmol)と組み合わせた。45分間撹拌した後、反応混合物を10mLのジクロロメタンで希釈し、水(3×)及び飽和食塩水で洗浄した。有機部分をNa2SO4で乾燥させ、濾過し、減圧下で濃縮した。カラムクロマトグラフィー(SiO2、33%CMA/クロロホルムから50%CMA)による精製によって、淡褐色のシロップを得た。このシロップを、30mLのジクロロメタンに溶解させ、1N NaOH溶液(2×)、水、及び飽和食塩水で連続的に洗浄した。有機部分をNa2SO4で乾燥させ、濾過し、減圧下で濃縮した。カラムクロマトグラフィー(SiO2、2.5%メタノール/クロロホルムから10%メタノール/クロロホルム)による更なる精製は、71mgのtert−ブチルN−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]カルバメートの淡褐色のシロップをもたらした。
5mLのエタノールに溶解させたtert−ブチルN−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]カルバメート(71mg、0.172mmol)の溶液を、0.5mLの濃塩酸溶液と組み合わせた。混合物を90℃に60分間加熱し、次いで、減圧下で濃縮した。得られたシロップをエタノールから濃縮して、硬い白色の泡として、62mgの1−[(1S)−4−アミノ−1−(エトキシメチル)ブチル]イミダゾ[4,5−c]キノリン−4−アミン二塩酸塩を得た。
1.2mLの無水N,N−ジメチルホルムアミド(dimethylformamide、DMF)に溶解させた1−[(1S)−4−アミノ−1−(エトキシメチル)ブチル]イミダゾ[4,5−c]キノリン−4−アミン二塩酸塩(62mg、0.16mmol)の溶液を、トリエチルアミン(67μL、0.48mmol)及びステアロイルクロリド(50mg、0.16mmol)と組み合わせた。90分間撹拌した後、反応混合物を2mLのジクロロメタンと組み合わせ、撹拌を90分間継続した。反応混合物を、20mLのジクロロメタン及び水で希釈した。少量のメタノールを添加し、得られたエマルションを分解した。層同士を分離し、有機部分を水(2×)及び飽和食塩水で洗浄した。有機部分をNa2SO4で乾燥させ、濾過し、減圧下で濃縮した。カラムクロマトグラフィー(SiO2、2.5%メタノール/クロロホルムから10%メタノール/クロロホルム)による精製によって、46mgの固体を得た。2mLの高温アセトニトリルからの結晶化は、白色粉末として、38mgのN−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]オクタデカンアミドをもたらした。1H NMR(CD3OD,500MHz)δ8.41(s,1H),8.27(d,J=8.2Hz,1H),7.74(d,J=8.3Hz,1H),7.54(t,J=7.7Hz,1H),7.38(t,J=7.6Hz,1H),5.39(m,1H),4.01(dd,J=5.8,10.4Hz,1H),3.93(dd,J=3.8,10.4Hz,1H),3.52(q,J=7.0Hz,2H),3.22(m,2H),2.19(m,2H),2.14(t,J=7.4Hz,2H),1.63−1.51(m,4H),1.32−1.23(m,24H),1.12(t,J=7.0Hz,3H),0.92(t,J=7.0Hz,3H)。
15mLの無水THF中に溶解させたN−δ−BOC−N−α−CBZ−L−オルニチン(4.71g、12.9mmol)の撹拌溶液を、氷/メタノール浴において−15℃に冷却した。溶液にN−メチルモルホリン(1.43mL、13.0mmol)を添加し、続いてイソブチルクロロホルメート(1.69mL、13.0mmol)を添加した。5分間撹拌した後、反応混合物を濾過し、少量のTHFですすぎ、N−メチルモルホリン塩酸塩を除去した。得られた濾液を冷浴に戻し、7mLのH2O中、1.00gのNaBH4の溶液を注意深く添加した。20分間撹拌した後、反応混合物を100mLの水と組み合わせ、続いて100mLの酢酸エチルを添加した。層同士を分離し、追加の25mLの酢酸エチルで水性部分を抽出した。組み合わせた有機部分を水及び飽和食塩水で洗浄し、Na2SO4で乾燥させ、濾過し、濃縮して無色のシロップを得た。シロップをエタノールから濃縮して、白色固体として、4.22gのtert−ブチルN−[(4S)−4−(ベンジルオキシカルボニルアミノ)−5−ヒドロキシ−ペンチル]カルバメートをもたらした。
50mLのメタノール中のtert−ブチルN−[(4S)−4−(ベンジルオキシカルボニルアミノ)−5−ヒドロキシ−ペンチル]カルバメート(4.22g、12.0mmol)の溶液を圧力ボトルに入れ、300mgの炭素担持10%パラジウムを添加した。次いで、水素(40PSI)雰囲気下、ボトルを終夜振盪した。反応混合物をセライトのパッドを通して濾過し、MeOHですすぎ、減圧下で濾液を濃縮して、無色のシロップとして、2.61gのtert−ブチルN−[(4S)−4−アミノ−5−ヒドロキシ−ペンチル]カルバメートを得た。
50mLのジクロロメタンに溶解させたtert−ブチルN−[(4S)−4−アミノ−5−ヒドロキシ−ペンチル]カルバメート(2.61g、12.0mmol)の溶液を、4−クロロ−3−ニトロキノリン(2.49g、12.0mmol)及びトリエチルアミン(3.33mL、23.9mmol)と組み合わせ、反応混合物を窒素雰囲気下で終夜撹拌した。反応混合物を濃縮し、黄色固体を得た。この固体を、125mLの酢酸エチルに溶解させ、水(3×)及び飽和食塩水で洗浄した。有機部分をNa2SO4で乾燥させ、濾過し、濃縮して、黄色固体として、4.23gのtert−ブチルN−[(4S)−5−ヒドロキシ−4−[(3−ニトロ−4−キノリル)アミノ]ペンチル]カルバメートを得た。
125mLのアセトニトリル中のtert−ブチルN−[(4S)−5−ヒドロキシ−4−[(3−ニトロ−4−キノリル)アミノ]ペンチル]カルバメート(4.23g、10.8mmol)の懸濁液を圧力ボトルに入れ、200mgの炭素担持3%白金を添加した。次いで、水素(40PSI)雰囲気下、ボトルを4時間振盪した。反応混合物をセライトのパッドを通して濾過し、アセトニトリルですすぎ、減圧下で濾液を濃縮して、橙色の泡として、3.80gのtert−ブチルN−[(4S)−4−[(3−アミノ−4−キノリル)アミノ]−5−ヒドロキシ−ペンチル]カルバメートを得た。
40mLの酢酸n−プロピル中に溶解させたtert−ブチルN−[(4S)−4−[(3−アミノ−4−キノリル)アミノ]−5−ヒドロキシ−ペンチル]カルバメート(3.80g、10.6mmol)の溶液を、トリエチルオルトホルメート(3.50mL、21.1mmol)及び300mgのピリジン塩酸塩と組み合わせ、混合物を105℃に2日間加熱した。冷却した反応混合物を50mLの酢酸エチルで希釈し、飽和NaHCO3溶液、水、及び飽和食塩水で連続的に洗浄した。有機部分をNa2SO4で乾燥させ、濾過し、濃縮して、淡褐色のシロップを得た。カラムクロマトグラフィー(SiO2、1%メタノール/クロロホルムから10%メタノール/クロロホルム)による精製は、白色の泡として、2.40gのtert−ブチルN−[(4S)−5−ヒドロキシ−4−イミダゾ[4,5−c]キノリン−1−イル−ペンチル]カルバメートをもたらした。
200mLの丸底(bound bottom)フラスコに、1.04gの50%NaOH水溶液、及び150mgのテトラブチルアンモニウムクロリド水和物を投入した。40mLの高温トルエンに溶解させたtert−ブチルN−[(4S)−5−ヒドロキシ−4−イミダゾ[4,5−c]キノリン−1−イル−ペンチル]カルバメート(2.00g、5.40mmol)の溶液を添加し、反応混合物を85℃に加熱した。ジエチルサルフェート(886μL、6.77mmol)を添加し、混合物を4時間撹拌した。反応混合物を冷却し、10mLの飽和NH4OH溶液でクエンチした。75分間撹拌した後、反応物を水及びトルエンと組み合わせ、層同士を分離した。有機層をH2O(2×)及び飽和食塩水で連続的に洗浄し、Na2SO4で乾燥させ、濾過し、減圧下で濃縮して、無色のシロップを得た。カラムクロマトグラフィー(SiO2、20%酢酸エチル/ヘキサンから50%酢酸エチル)による精製は、金色のシロップとして、888mgのtert−ブチルN−[(4S)−5−エトキシ−4−イミダゾ[4,5−c]キノリン−1−イル−ペンチル]カルバメートをもたらした。
実施例1のG及びH剤の手順に従って、321mg(0.832mmol)の1−[(1S)−4−アミノ−1−(エトキシメチル)ブチル]イミダゾ[4,5−c]キノリン−4−アミン二塩酸塩をもたらした。この化合物を5mLの無水DMFに溶解させ、トリエチルアミン(347μL、2.50mmol)及びミリストイルクロリド(226μL、0.832mmol)と組み合わせた。終夜撹拌した後、25mLの水を反応混合物に添加した。得られた固体を濾過によって単離し、水ですすぎ、10%メタノール/クロロホルムに溶解させ、次いで減圧下で濃縮し、ワックス状固体を得た。カラムクロマトグラフィー(SiO2、2%メタノール/クロロホルムから15%メタノール/クロロホルム)による精製によって、淡褐色固体を得た。アセトニトリルからの結晶化は、淡褐色固体として、30mgのN−[(4S)−4−(4−アミノイミダゾ[4,5−c]キノリン−1−イル)−5−エトキシ−ペンチル]テトラデカンアミドをもたらした。1H NMR(CD3OD,500MHz)δ8.42(s,1H),8.29(d,J=8.1Hz,1H),7.75(d,J=8.3Hz,1H),7.56(t,J=7.7Hz,1H),7.40(t,J=7.6Hz,1H),5.40(m,1H),4.01(dd,J=5.4,10.0Hz,1H),3.93(dd,J=3.0,10.2Hz,1H),3.52(q,J=6.9Hz,2H),3.22(m,2H),2.27−2.08(m,4H),1.64−1.50(m,4H),1.39−1.21(m,20H),1.11(t,J=7.0Hz,3H),0.91(t,J=6.8Hz,3H)。
健康なヒト供与者からの全血を、静脈穿刺によって、EDTAが入ったバキュテイナー管又はシリンジに採取した。密度勾配遠心分離により、ヒト末梢血単核球(peripheral blood mononuclear cell、PBMC)を全血から精製した。Histopaque 1077(15mL、Sigma(St.Louis,MO))を、6×50mL滅菌ポリプロピレンコニカルチューブに移した。Histopaqueに、ハンクス平衡塩溶液(Hank’s Balanced Salts Solution、HBSS)(Gibco,Life Technology(Grand Island NY))で1:2に希釈した15〜25mLの血液を重層した。次いで、このチューブを、1370rpm、30分間、20℃で、中断なく遠心分離した(400×g、GH 3.8A Rotor)。
Claims (15)
- 式(I)
nは、0又は1の整数であり、
Rは、ハロゲン、ヒドロキシ、アルキル、アルコキシ、及び−C(O)−O−アルキルからなる群から選択され、
Xはアルキレンであり、前記アルキレン基は、1つ以上の−O−基により任意に介在されていてもよく、
R1は、C1−5アルキル及び−C1−3アルキレン−O−C1−3アルキルからなる群から選択され、
R2は、水素、メチル、エチル、n−プロピル、n−ブチル、−CH2OCH3、−CH2OCH2CH3、及び−CH2CH2OCH3からなる群から選択され、
R3はアルキルであり、前記アルキル基は、1つ以上の−O−基により任意に介在されていてもよく、
R4は、水素、メチル、エチル、n−プロピル、及びイソプロピルからなる群から選択される]
の化合物、又は製薬上許容されるその塩。 - XがC1−8アルキレンである、請求項1に記載の化合物又は塩。
- Xが、−CH2−、−CH2CH2−、−CH2CH2CH2−、−CH2CH2CH2CH2−、−CH2CH2CH2CH2CH2−、−CH2CH2CH2CH2CH2CH2−、−CH2CH2CH2CH2CH2CH2CH2−、及び−CH2CH2CH2CH2CH2CH2CH2CH2−からなる群から選択される、請求項1又は2に記載の化合物又は塩。
- R1が、−CH2OCH3又は−CH2OCH2CH3である、請求項1〜3のいずれか一項に記載の化合物又は塩。
- R2が、水素、メチル、及びエチルからなる群から選択される、請求項1〜4のいずれか一項に記載の化合物又は塩。
- R2が水素である、請求項1〜5のいずれか一項に記載の化合物又は塩。
- R3がC5−19アルキルである、請求項1〜6のいずれか一項に記載の化合物又は塩。
- R3が−CH2(CH2)3−17CH3である、請求項1〜7のいずれか一項に記載の化合物又は塩。
- Rが、ヒドロキシ、F、及びClからなる群から選択される、請求項1〜7のいずれか一項に記載の化合物又は塩。
- nが0である、請求項1〜9のいずれか一項に記載の化合物又は塩。
- R4が水素である、請求項1〜10のいずれか一項に記載の化合物又は塩。
- ワクチンアジュバントとして使用するための、請求項1〜11のいずれか一項に記載の化合物又は塩。
- 請求項1に記載の化合物又は塩の有効量を、ヒト又は動物に投与することを含む、ヒト又は動物においてIFN−αの生合成を誘導する方法。
- 請求項1に記載の化合物又は塩の有効量を、ヒト又は動物に投与することを含む、ヒト又は動物においてTNF−αの生合成を誘導する方法。
- 請求項1に記載の化合物又は塩の治療有効量を、製薬上許容される担体と組み合わせて含む、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608334P | 2017-12-20 | 2017-12-20 | |
US62/608,334 | 2017-12-20 | ||
PCT/IB2018/060122 WO2019123178A1 (en) | 2017-12-20 | 2018-12-14 | Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021506891A true JP2021506891A (ja) | 2021-02-22 |
JP7197244B2 JP7197244B2 (ja) | 2022-12-27 |
Family
ID=65234596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020534235A Active JP7197244B2 (ja) | 2017-12-20 | 2018-12-14 | 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ[4,5-c]キノリン化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11306083B2 (ja) |
EP (1) | EP3728255B1 (ja) |
JP (1) | JP7197244B2 (ja) |
CN (1) | CN111511740B (ja) |
CA (1) | CA3086439A1 (ja) |
WO (1) | WO2019123178A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111788202B (zh) | 2018-02-28 | 2024-03-01 | 3M创新有限公司 | 具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物 |
US11884662B2 (en) | 2018-05-24 | 2024-01-30 | 3M Innovative Properties Company | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001502699A (ja) * | 1996-10-25 | 2001-02-27 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Th2介在性および関連疾患治療のための免疫応答修飾化合物 |
JP2003501466A (ja) * | 1999-06-10 | 2003-01-14 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾキノリン |
JP2007521317A (ja) * | 2003-08-14 | 2007-08-02 | スリーエム イノベイティブ プロパティズ カンパニー | 脂質修飾された免疫応答調整剤 |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3314941A (en) | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
US3700674A (en) | 1969-04-30 | 1972-10-24 | American Cyanamid Co | 4-alkylamino-3-nitroquinolines |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
DK0553202T3 (da) | 1990-10-05 | 1995-07-03 | Minnesota Mining & Mfg | Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer |
US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
CZ288182B6 (en) | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5644063A (en) | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
JPH09176116A (ja) | 1995-12-27 | 1997-07-08 | Toray Ind Inc | 複素環誘導体およびその医薬用途 |
JPH09208584A (ja) | 1996-01-29 | 1997-08-12 | Terumo Corp | アミド誘導体、およびそれを含有する医薬製剤、および合成中間体 |
US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
EP0894797A4 (en) | 1997-01-09 | 2001-08-16 | Terumo Corp | NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS |
JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体 |
UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
JPH11222432A (ja) | 1998-02-03 | 1999-08-17 | Terumo Corp | インターフェロンを誘起するアミド誘導体を含有する外用剤 |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
ATE304852T1 (de) | 1999-01-08 | 2005-10-15 | 3M Innovative Properties Co | Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie |
US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
JP2000247884A (ja) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6756382B2 (en) * | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US6894060B2 (en) | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
US20020055517A1 (en) | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
JP2002145777A (ja) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US20020107262A1 (en) | 2000-12-08 | 2002-08-08 | 3M Innovative Properties Company | Substituted imidazopyridines |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
AU2006216669A1 (en) | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
KR100455713B1 (ko) | 2001-01-29 | 2004-11-06 | 호남석유화학 주식회사 | 올레핀 중합용 다중핵 메탈로센 촉매 및 이를 이용한중합방법 |
US7226928B2 (en) | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
EP1427445A4 (en) | 2001-08-30 | 2006-09-06 | 3M Innovative Properties Co | METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES |
EP1434579B1 (en) | 2001-10-09 | 2011-06-08 | Amgen Inc. | Imidazole derivatives as antiinflammatory agents |
JP2005519990A (ja) | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物 |
PT1719511E (pt) | 2001-11-16 | 2009-03-06 | Coley Pharm Group Inc | N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização |
NZ532769A (en) * | 2001-11-29 | 2005-12-23 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune response modifier |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
CA2475595C (en) | 2002-02-22 | 2012-07-10 | 3M Innovative Properties Company | Method of reducing and preventing uvb-induced immunosuppression |
ATE491471T1 (de) | 2002-03-19 | 2011-01-15 | Powderject Res Ltd | Adjuvantien für dns impstoffe basierend auf imidazochinoline |
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
AU2003233519A1 (en) | 2002-05-29 | 2003-12-19 | 3M Innovative Properties Company | Process for imidazo(4,5-c)pyridin-4-amines |
NZ537054A (en) | 2002-06-07 | 2006-10-27 | 3M Innovative Properties Co | Ether substituted imidazopyridines |
DK1543002T3 (da) | 2002-07-23 | 2006-12-27 | Teva Gyogyszergyar Zartkoeruee | Fremstilling af 1H-imidazo (4,5-c) quinolin-4-aminer via 1H-imidazo (4,5-c) quinolin-4-phtalimid mellemprodukter |
DK1539752T3 (da) | 2002-07-26 | 2007-07-16 | Teva Gyogyszergyar Zartkoeruee | Fremstilling af 1H-imidazo(4,5-c)quinolin-4-aminer via ny imidazo(4,5-c)quinolin 4-cyano og 1H-imidazo(4,5-c)quinolin-4-carboxamid mellemprodukter |
EP2269632B1 (en) | 2002-08-15 | 2014-01-01 | 3M Innovative Properties Co. | Immunostimulatory compositions and methods of stimulating an immune response |
AU2003299082A1 (en) | 2002-09-26 | 2004-04-19 | 3M Innovative Properties Company | 1h-imidazo dimers |
AU2003287324A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
AU2003287316A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
NZ540826A (en) | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
CN1747953A (zh) * | 2002-12-20 | 2006-03-15 | 3M创新有限公司 | 芳基/杂芳基取代的咪唑并喹啉 |
AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
WO2004071459A2 (en) | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
US7485432B2 (en) | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
US8110582B2 (en) | 2003-03-04 | 2012-02-07 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
US7163947B2 (en) | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
JP2006520245A (ja) | 2003-03-13 | 2006-09-07 | スリーエム イノベイティブ プロパティズ カンパニー | 入れ墨の除去方法 |
CA2518282C (en) | 2003-03-13 | 2012-11-06 | 3M Innovative Properties Company | Methods of improving skin quality |
CA2518082C (en) | 2003-03-13 | 2013-02-12 | 3M Innovative Properties Company | Methods for diagnosing skin lesions |
EP1613956A2 (en) | 2003-03-25 | 2006-01-11 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
EP1617871A4 (en) | 2003-04-10 | 2010-10-06 | 3M Innovative Properties Co | DISTRIBUTION OF IMMUNE-RESPONSE-MODIFYING COMPOUNDS USING PARTICULATE CARRIER MATERIALS CONTAINING METAL |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
US20040214851A1 (en) | 2003-04-28 | 2004-10-28 | 3M Innovative Properties Company | Compositions and methods for induction of opioid receptors |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
AR044466A1 (es) | 2003-06-06 | 2005-09-14 | 3M Innovative Properties Co | Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas |
WO2004110991A2 (en) | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
MY157827A (en) | 2003-06-27 | 2016-07-29 | 3M Innovative Properties Co | Sulfonamide substituted imidazoquinolines |
US20050106300A1 (en) | 2003-06-30 | 2005-05-19 | Purdue Research Foundation | Method for producing a material having an increased solubility in alcohol |
KR20060054371A (ko) | 2003-07-31 | 2006-05-22 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 캡슐화 및 제어된 방출을 위한 조성물 |
JP2007501252A (ja) | 2003-08-05 | 2007-01-25 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調整剤を含有する製剤 |
BRPI0412902A (pt) | 2003-08-12 | 2006-09-26 | 3M Innovative Properties Co | compostos contendo imidazo substituìdo por oxima |
CA2535338C (en) | 2003-08-14 | 2013-05-28 | 3M Innovative Properties Company | Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers |
JP2007504145A (ja) | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫刺激性の組み合わせおよび治療 |
CA2536249A1 (en) | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
ES2406730T3 (es) | 2003-08-27 | 2013-06-07 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi |
CA2536578A1 (en) | 2003-09-02 | 2005-03-10 | 3M Innovative Properties Company | Methods related to the treatment of mucosal associated conditions |
CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
OA13310A (en) | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
WO2005029037A2 (en) | 2003-09-17 | 2005-03-31 | 3M Innovative Properties Company | Selective modulation of tlr gene expression |
WO2005033049A2 (en) | 2003-10-01 | 2005-04-14 | Taro Pharmaceuticals U.S.A., Inc. | METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF |
US20090075980A1 (en) | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
RU2412942C2 (ru) | 2003-10-03 | 2011-02-27 | 3М Инновейтив Пропертиз Компани | Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
JP2007509987A (ja) | 2003-10-31 | 2007-04-19 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤化合物による好中球活性化 |
ITMI20032121A1 (it) | 2003-11-04 | 2005-05-05 | Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm | Procedimento per la preparazione di imiquimod e suoi intermedi |
AU2004291101A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
EP1682544A4 (en) | 2003-11-14 | 2009-05-06 | 3M Innovative Properties Co | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS |
EP1687305B1 (en) | 2003-11-21 | 2008-07-09 | Novartis AG | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
AU2004293096A1 (en) | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
MY161812A (en) | 2003-11-25 | 2017-05-15 | 3M Innovative Properties Co | Substituted imidazo ring systems and methods |
WO2005055932A2 (en) | 2003-12-02 | 2005-06-23 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
CN1914203A (zh) | 2003-12-04 | 2007-02-14 | 3M创新有限公司 | 砜取代的咪唑环醚 |
EP1701955A1 (en) | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
AU2004312510A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds |
EP1699398A4 (en) | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | IMPROVING THE IMMUNE RESPONSE |
US20050158325A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
AU2004312508A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
CA2559607C (en) | 2004-03-15 | 2013-02-19 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
AU2005228150A1 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
JP2007532572A (ja) | 2004-04-09 | 2007-11-15 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応調整剤を送達させるための方法、組成物および調製物 |
US20060051374A1 (en) | 2004-04-28 | 2006-03-09 | 3M Innovative Properties Company | Compositions and methods for mucosal vaccination |
US20080015184A1 (en) | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
US20070259907A1 (en) | 2004-06-18 | 2007-11-08 | Prince Ryan B | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US7884207B2 (en) | 2004-06-18 | 2011-02-08 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
EP1786450A4 (en) | 2004-08-27 | 2009-11-11 | 3M Innovative Properties Co | HIV IMMUNOSTIMATORY COMPOSITIONS |
US20060045885A1 (en) | 2004-08-27 | 2006-03-02 | Kedl Ross M | Method of eliciting an immune response against HIV |
WO2006026760A2 (en) | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
WO2006029115A2 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
CA2578741C (en) | 2004-09-02 | 2014-01-14 | 3M Innovative Properties Company | 1-alkoxy 1h-imidazo ring systems and methods |
WO2006028451A1 (en) | 2004-09-03 | 2006-03-16 | 3M Innovative Properties Company | 1-amino 1-h-imidazoquinolines |
WO2006029223A2 (en) | 2004-09-08 | 2006-03-16 | Children's Medical Center Corporation | Method for stimulating the immune response of newborns |
WO2006031878A2 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
WO2006042254A2 (en) | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
US20100113565A1 (en) | 2004-12-08 | 2010-05-06 | Gorden Keith B | Immunostimulatory combinations and methods |
WO2006063072A2 (en) | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
JP5543068B2 (ja) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
AU2005326708C1 (en) | 2004-12-30 | 2012-08-30 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
NZ556399A (en) | 2004-12-30 | 2009-03-31 | Takeda Pharmaceutical | 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate |
JP2008526765A (ja) | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | 皮膚転移の処置 |
US8436176B2 (en) | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
EP1830880A4 (en) | 2004-12-30 | 2008-03-26 | Coley Pharm Group Inc | MULTI-CHANNEL ADMINISTRATION OF IMMUNE RESPONSE MODIFIER COMPOUNDS |
ATE545010T1 (de) | 2005-02-02 | 2012-02-15 | Mocon Inc | Instrument und verfahren zum detektieren und melden der grösse von lecks in hermetisch abgedichteten verpackungen |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
CA2602083A1 (en) | 2005-02-09 | 2006-08-09 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods |
AU2006212765B2 (en) | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
US7968563B2 (en) | 2005-02-11 | 2011-06-28 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
CA2597446A1 (en) | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
AU2006213745A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods |
CA2598437A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
WO2006091567A2 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
CA2598695A1 (en) | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
EP1851220A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazonaphthyridines |
WO2006099275A2 (en) | 2005-03-14 | 2006-09-21 | 3M Innovative Properties Company | Method of treating actinic keratosis |
AU2006244635A1 (en) | 2005-04-01 | 2006-11-16 | Coley Pharmaceutical Group, Inc. | Ring closing and related methods and intermediates |
EP1869043A2 (en) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
EP1863814A1 (en) | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
EP1863813A2 (en) | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods |
EP1874345B1 (en) | 2005-04-25 | 2012-08-15 | 3M Innovative Properties Company | Immunostimulatory compositions |
WO2007028129A1 (en) | 2005-09-02 | 2007-03-08 | Pfizer Inc. | Hydroxy substituted 1h-imidazopyridines and methods |
AU2006287270A1 (en) | 2005-09-09 | 2007-03-15 | Coley Pharmaceutical Group, Inc. | Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
BRPI0616338A2 (pt) | 2005-09-23 | 2011-06-14 | Coley Pharm Group Inc | mÉtodo para 1h-imidazo[4,5-c] piridinas e anÁlogos da mesma |
CA2628131C (en) | 2005-11-04 | 2012-03-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods |
JP2009522296A (ja) | 2005-12-28 | 2009-06-11 | スリーエム イノベイティブ プロパティズ カンパニー | 皮膚のt細胞リンパ腫の治療 |
US20090306388A1 (en) | 2006-02-10 | 2009-12-10 | Pfizer Inc. | Method for substituted ih-imidazo[4,5-c] pyridines |
EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
US8329721B2 (en) | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
US20100028381A1 (en) | 2006-06-19 | 2010-02-04 | 3M Innovative Properties Company | Formulation for delivery of immune response modifiers |
WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
US8124096B2 (en) | 2006-07-31 | 2012-02-28 | 3M Innovative Properties Company | Immune response modifier compositions and methods |
US8178539B2 (en) | 2006-09-06 | 2012-05-15 | 3M Innovative Properties Company | Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
JP5400763B2 (ja) | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
NZ599446A (en) * | 2008-03-24 | 2013-11-29 | 4Sc Discovery Gmbh | Novel substituted imidazoquinolines |
US9242980B2 (en) | 2010-08-17 | 2016-01-26 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
JP6415979B2 (ja) | 2011-06-03 | 2018-10-31 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドラジノ1h−イミダゾキノリン−4−アミン及びこれから調製された複合体 |
WO2013033345A1 (en) | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
WO2014201245A1 (en) * | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
EP3134402B1 (en) | 2014-04-22 | 2020-05-06 | F.Hoffmann-La Roche Ag | 4-amino-imidazoquinoline compounds |
MX2018002017A (es) | 2015-08-31 | 2018-03-26 | 3M Innovative Properties Co | Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina. |
-
2018
- 2018-12-14 US US15/733,207 patent/US11306083B2/en active Active
- 2018-12-14 WO PCT/IB2018/060122 patent/WO2019123178A1/en unknown
- 2018-12-14 CA CA3086439A patent/CA3086439A1/en active Pending
- 2018-12-14 CN CN201880081901.4A patent/CN111511740B/zh active Active
- 2018-12-14 EP EP18839861.4A patent/EP3728255B1/en active Active
- 2018-12-14 JP JP2020534235A patent/JP7197244B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001502699A (ja) * | 1996-10-25 | 2001-02-27 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Th2介在性および関連疾患治療のための免疫応答修飾化合物 |
JP2003501466A (ja) * | 1999-06-10 | 2003-01-14 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾキノリン |
JP2007521317A (ja) * | 2003-08-14 | 2007-08-02 | スリーエム イノベイティブ プロパティズ カンパニー | 脂質修飾された免疫応答調整剤 |
Also Published As
Publication number | Publication date |
---|---|
JP7197244B2 (ja) | 2022-12-27 |
EP3728255A1 (en) | 2020-10-28 |
CA3086439A1 (en) | 2019-06-27 |
EP3728255B1 (en) | 2022-01-26 |
US20210101898A1 (en) | 2021-04-08 |
WO2019123178A1 (en) | 2019-06-27 |
CN111511740B (zh) | 2023-05-16 |
CN111511740A (zh) | 2020-08-07 |
US11306083B2 (en) | 2022-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7010286B2 (ja) | グアニジノ基で置換された縮合[1,2]イミダゾ[4,5-c]環状化合物 | |
JP6956070B2 (ja) | グアニジン置換イミダゾ[4,5−c]環状化合物 | |
CN111788202B (zh) | 具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物 | |
JP6956071B2 (ja) | 置換グアニジン基を含有するイミダゾ[4,5−c]環状化合物 | |
JP2021506891A (ja) | 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ[4,5−c]キノリン化合物 | |
US12024514B2 (en) | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | |
CN113906027A (zh) | 具有N-1支链基团的苯乙基取代的咪唑并[4,5-c]喹啉化合物 | |
US20220177471A1 (en) | N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | |
JP7394790B2 (ja) | N-1分枝状シクロアルキル置換イミダゾ[4,5-c]キノリン化合物、組成物、及び方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211213 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211213 |
|
TRDD | Decision of grant or rejection written | ||
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221110 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221212 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7197244 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |